Home Newsfeeds CDC Director Walensky Says Anticipate Increase In Monkeypox Cases In Coming Weeks Due To Increased Testing

CDC Director Walensky Says Anticipate Increase In Monkeypox Cases In Coming Weeks Due To Increased Testing

-Reuters

byBenzinga Newsdesk

July 15, 2022

1 minute read

-Reuters

Edward Snowden Says If He Ever Claims To Be Bitcoin Creator Satoshi Nakamoto It’s Either Him Trolling Or A ‘Duress Code’

By Mehab Qureshi

February 19, 11:54 PM

Former National Security Agency contractor and whistleblower Edward Snowden on Monday said that should he ever claim to be ‘Satoshi Nakamoto’, the pseudonym used by Bitcoin’s (CRYPTO: BTC) founder, the public should scrutinize his claim.

BTC

Why Tivic Health (TIVC) Stock Is Down Over 40%

By Henry Khederian

July 10, 9:55 AM

Tivic Health Systems Inc (NASDAQ: TIVC) shares are trading lower by 46% to $0.059 Monday morning after the company priced its public offering of 32.5 million shares at

TIVC

Reported Late Wednesday, G1 Therapeutics Provides Initial Results From Phase 2 Mechanism Of Action Trial In Early-Stage Triple Negative Breast Cancer Show That A Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment

By Benzinga Newsdesk

December 8, 3:13 AM

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided initial results from a 24 patient Phase 2 mechanism of action (MOA) trial showing favorable alterations in the tumor

GTHX

A Look At The SPY Ahead of Key Fed Meeting, Turbo Earnings Week: What To Watch

By Melanie Schaffer

February 1, 1:07 PM

The SPDR S&P 500 (NYSE: SPY) was trading lower on Wednesday, consolidating with an inside bar as the stock market awaits the Federal Reserve's decision on fed fund rates, which is

SPY

CDC Director Walensky Says Anticipate Increase In Monkeypox Cases In Coming Weeks Due To Increased Testing

Related Posts

Edward Snowden Says If He Ever Claims To Be Bitcoin Creator Satoshi Nakamoto It’s Either Him Trolling Or A ‘Duress Code’

Why Tivic Health (TIVC) Stock Is Down Over 40%

Reported Late Wednesday, G1 Therapeutics Provides Initial Results From Phase 2 Mechanism Of Action Trial In Early-Stage Triple Negative Breast Cancer Show That A Single Dose Of Trilaciclib Favorably Alters The Tumor Microenvironment

A Look At The SPY Ahead of Key Fed Meeting, Turbo Earnings Week: What To Watch